Monitor the December 9, 2026 special meeting vote on the Required Proposals and the resolution of the Section 205 Action, as failure of either could prevent the merger. Also watch for Nasdaq listing approval for the combined company under the AVRX symbol.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Oct 30 $5.70entry
- T+1 · 2d ago +3.78%α +3.48% · $5.91
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 26d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NextCure filed Amendment No. 2 to its S-4 registration statement for the proposed reverse merger with Avere Therapeutics. Under the Merger Agreement, Avere will merge into a NextCure subsidiary, with Avere's stockholders receiving NextCure common stock based on an estimated exchange ratio of 6.9730, and NextCure will be renamed Avere Therapeutics, Inc. The transaction includes an $820.0 million Avere pre-closing financing, and existing NextCure stockholders are expected to own only approximately 0.99% of the combined company, with Avere's pre-closing financing investors owning approximately 59.32%.
Key Facts
- NextCure and Avere entered into a Merger Agreement on July 14, 2026, under which Avere will merge into a NextCure subsidiary, with NextCure renamed Avere Therapeutics, Inc.
- The exchange ratio is estimated at 6.9730 shares of NextCure common stock per share of Avere capital stock, based on a $250.0 million valuation for Avere and an $11.0 million valuation for NextCure.
- Existing NextCure securityholders are expected to own approximately 0.99% of the combined company, former Avere holders (excluding pre-closing financing) approximately 39.69%, and Avere pre-closing financing investors approximately 59.32%.
- Avere pre-closing financing totals $820.0 million, comprising $320.0 million initial commitments and $500.0 million additional commitments, with approximately $266.0 million of the total satisfied by conversion of convertible notes.
- NextCure stockholders will receive one CVR per share, representing the right to 90% of net proceeds from disposition of NextCure's legacy assets.
- NextCure's net cash at closing is estimated at approximately $(2.7) million, and NextCure has substantial doubt about its ability to continue as a going concern.
- The combined company's board will consist of six Avere designees, and Avere's management team will lead the combined company.
- The combined company's common stock is expected to trade on Nasdaq under the symbol AVRX, subject to Nasdaq listing approval.
- NextCure has filed a Section 205 Action in Delaware Court of Chancery seeking validation of its 2025 reverse stock split amendment.
- NextCure's net losses were $24.7 million and $37.8 million for the six months ended June 30, 2026 and 2025, respectively, with an accumulated deficit of $460.7 million as of June 30, 2026.
Financial Impact
Existing NextCure stockholders are diluted to approximately 0.99% ownership of the combined company. The transaction ascribes a $250.0 million valuation to Avere and $11.0 million to NextCure. Avere pre-closing financing of $820.0 million, with $266.0 million via convertible note conversion. NextCure net cash at closing estimated at $(2.7) million.
Risk Factors
- Merger may not close if Required Proposals are not approved or Nasdaq listing condition is not met.
- NextCure stockholders face extreme dilution, owning only ~0.99% of the combined company.
- NextCure has substantial doubt about its ability to continue as a going concern if the merger does not close.
- Pending Section 205 Action regarding the validity of the 2025 reverse stock split could delay or prevent the merger.
- CVRs may expire valueless if legacy assets are not monetized.
- The combined company depends on a single product candidate, AVR-001, which is in early clinical development and in-licensed from Hansoh.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001104659-26-120808 |
| Document: nxtc-ex10d54.htm | 0001104659-26-120808 |
| Document: nxtc-ex10d46.htm | 0001104659-26-120808 |
| Document: nxtc-ex3d3.htm | 0001104659-26-120808 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 4d ago | S-4/A | $5.70 | awaiting T+60 | awaiting T+60 | $5.93 (−4.13%) |
Oct 30, 2026 5d ago | 8-K | $6.31 | awaiting T+60 | awaiting T+60 | $5.93 (−6.02%) |
Oct 20, 2026 15d ago | SC 13G | $5.44 | awaiting T+60 | awaiting T+60 | $5.93 (+9.01%) |
Sep 25, 2026 5w ago | 425 | $5.08 | awaiting T+60 | awaiting T+60 | $5.93 (+16.73%) |
Sep 25, 2026 5w ago | 8-K | $5.08 | awaiting T+60 | awaiting T+60 | $5.93 (+16.73%) |
Aug 10, 2026 12w ago | 425 | $6.73 | awaiting T+60 | awaiting T+60 | $5.93 (+11.89%) |
Aug 4, 2026 13w ago | 425 | $5.78 $5.72 | ▼ −1.12% | ▼ −1.50% | $5.93 (+2.60%) |
Aug 3, 2026 13w ago | Insider Buy | $5.78 $5.72 | ▼ −1.12% | ▼ −1.50% | $5.93 (+2.60%) |
Jul 29, 2026 13w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.93 (+17.89%) |
Jul 14, 2026 16w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.93 (−9.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers